Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 193557

AbstractConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Reviews
Year : 2023 | Month : February | Volume : 17 | Issue : 2 | Page : ME01 - ME05 Full Version

Post COVID Mucormycosis- A Narrative Review


Published: February 1, 2023 | DOI: https://doi.org/10.7860/JCDR/2023/59617.17471
Sakshi Dinesh Firke, Prasad Deshmukh

1. Student, Department of Ear, Nose and Throat, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India. 2. Professor and Head, Department of Ear, Nose and Throat, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India.

Correspondence Address :
Sakshi Dinesh Firke,
4, Shanti Nagar, Yawal Road, Bhusawal, Maharashtra, India.
E-mail: hemakshiddf@gmail.com

Abstract

Mucormycosis is an Acute Invasive Fungal Rhinosinusitis (AIFR). Omnipresent fungi and their interaction with humans are both boon and a bane. Fungal rhinosinusitis is now becoming an alarming situation in today’s world, especially in India. It can be classified further into invasive or non invasive and acute or chronic. Categorisation helps us with its diagnosis and management. The invasion of the hyphae portrays mucormycosis into sinus tissue within less than four weeks. It comes with various predisposing factors such as underlying systemic disease, drug therapy, transplantation, and local lesion. Clinical manifestations such as headache, sinonasal congestion, black lesions on the nasal bridge, and facial inflammation associated with pain are prevalent in immunocompromised patients. Crucial steps such as early identification, definite treatment with a multidisciplinary integrated approach of various departments such as ENT, medicine, and radiology should be made. Intraorbital and intracranial complications can be prevented by treating disease process in the early stage.

Keywords

Coronavirus disease-2019, Diabetes, Nose, Paranasal sinuses, Sinusitis

Fungi have complicated interactions with all flora, fauna, and people due to their ubiquitous occurrence in the earth’s environment (1). Human-fungal interaction can be beneficial (symbiotic) or harmful (infection). A rough estimation of 200 out of 625 fungal species are human related among vertebrates (2). In one of his books, Nicholas Money said, “Time for panic attack: their spores are everywhere and, depending upon your location, you may have inhaled hundreds of them since beginning to read this chapter” (1). Mucormycosis is an uncommon astute fungal contamination caused by order mucorales of class zygomycetes, known for their angioinvasive nature (3),(4). Sexual (oospore, zygospore), as well as asexual (sporangiospores) spores, are formed by all fungi of order mucorales (5). Mucorales cultivated on routine laboratory media without chlorhexidine shows pronounced growth in 12-18 hours of plating (4). On histology, broad-based, non septate hyphae are seen at right angles to each other (6). Three commonly associated species with Mucormycosis are I#iRhizopus (most common), Mucor, and Rhizomucor; other species include Abisida, Cunninghamella, and Syncephalastrum (4),(6).

MUCORMYCOSIS IN COVID-19

Fungal rhinosinusitis once thought of as a rare disease, now being the biggest concern in the Indian subcontinent as it accounts for noteworthy cases of mucormycosis within the world. Having a 12.9 case yearly incidence between 1990 and 1999 to frequency of 22 instances annually in postCOVID-19 (Coronavirus Disease) era. The statistics show that India’s reported prevalence of mucormycosis is about 70 substantially larger than the estimated worldwide prevalence of 0.02-9.5 cases (with a median of 0.2 cases) per lac people (7). Fungi detection, evaluation of host immune status, and integrated approaches using biopsies, radiographic, microbiological, histopathological, and medical management with prompt surgical procedure help in a positive outcome (1). All these components in near future will help researcher to incorporate new methodologies and ideologies to decrease mortality and morbidity indicators. Although this condition was reported rarely in preCOVID-19 era but upsurge following COVID-19 pandemic with incidence of 22 cases yearly and median prevalence of 14 cases per lac people; associated anxiety among suffers and healthcare workers was increased (7). So, necessity to revisit the entity to explore its novelties prevails. In this narrative review, we retrieved the literature on fungal rhinosinusitis mucormycosis from PubMed, ScienceDirect, and Medicine Databases. While searching the various database, the advanced search option MeSH terms of words like fungal, rhinosinusitis, mucormycosis, paranasal sinuses, and nose was considered.

Classification

In the last 20 years, mucormycosis has surged gradually in countries like France, India, Belgium, and Switzerland (8). Also, Mucor is native to the Middle East and India. Modes of infection include inhalation or assemblage of spores in buccal, sinonasal or conjunctival mucosa (9). Based on pathological demonstration of tissue invasion by fungal components, the most widely accepted method developed by a consensus workshop divides fungal sinusitis into invasive and non invasive diseases (1). Mucormycosis was the old name for AIFR (10). Unlike non invasive fungal rhinosinusitis, AIFR principally shows invasion into neurological and vascular tissues (10). The proposed definition of AIFR includes the existence of fungal hyphae within the sinonasal mucosa, musculature, or a bone in the setting of sinusitis symptoms lasting one month or fewer (11). Initial phase of AIFR confined to sinonasal area have significantly lower fatality, whereas fatality rate doubles on progressive extension to intra cranial region (12). It is a fatal form of fungal sinusitis linked to a 50-80% death rate (10).

Predisposing/Risk Factors

Immunocompromised patients are more susceptible to mucormycosis AIFR (13). It is rapidly progressive, with a clinical course spanning from a few days to less than 4 weeks (1). Risk factors for mucormycosis include diabetic ketoacidosis, patients with haematolymphoid malignancy, haematopoietic stem cell and organ transplant recipients, patients on deferoxamine therapy, voriconazole administration, iron overload states, burn, and trauma patients. Long-term lymphopaenia in patients with severe COVID-19 may also influence their propensity to mucormycosis. Above mentioned different types of predisposing factors, result in the indistinct development of mucormycosis these risk factors can be further segregated into categories like underlying systemic disease, drug therapy, transplantation, and local lesion (Table/Fig 1) (3),(14).

Causative Agents

They belong to order mucorales of class zygomycetes (4). Three commonly associated species with Mucormycosis are Rhizopus (common), Lichtheimia, Apophysomyces, and Rhizomucor; other species include Mucor, Abisida, Cunninghamella, and Syncephalastrum [4,6,7]. Rhizopus subspecies such as R.arrhizus, R.microsporus, and R.homothallicus are commonly found in Indian soil. Among these, R.arrhizhus is very common, followed by other two showing frequent rise these years. Following Rhizopus, 60% of inflicted cases show Apophysomyces variabilis spp., securing second among India. Lichtheimia species accounts for 0.5% to 13% of cases from India, among them L. ramosa manifest as cutaneous mucormycosis (7).

Pathogenesis

There is significance of numerous predisposing aspects in mucormycosis pathogenesis. Pathogenic mechanism in particular predisposing factors such as diabetes mellitus with or without ketoacidosis, corticosteroids, and COVID-19 patients are elaborated below.

Role of diabetes mellitus with or without ketoacidosis: Ketoacidosis has a profound effect on mucormycosis, as basic physiology of cell which is carried out by iron is hampered (15). Due to the apparent occurrence of hyperglycaemia in diabetes, the innate immune system is compromised, resulting in inhibition of neutrophil relocation, chemotaxis, and reduced phagocytosis. By blocking the iron seclusion by transferrin and ferritin, the ketone bodies can result in enhanced accessibility of free iron. In susceptible hosts, elevated pH and enhanced accessibility of free iron encourage fungal proliferation (16). Acidic pH ranging between 7.3-6.88 and elevated free serum iron facilitates Rhizopus proliferation and activity [15,16]. Under provided acidic condition, iron binding capacity is decreased, which implies that acidosis (elevated H+), impairs iron and transferrin interaction via proton H+ mediated displacement of ferric ion from transferrin. Aspergillus fumigatus and Candida albicans cannot assimilate 8-fold and 40-fold more iron than Rhizopus can, according to in-vitro studies of radiolabelled iron uptake from deferoxamine in serum, respectively (15). Hyperglycaemia plays a role not only by blocking the activity of iron sequestering proteins, hindering neutrophil phagocytosis and chemotaxis but also by affecting the oxidative and non oxidative pathways and modulating GRP78, CotH3 (fungal protein) (17).

Role of corticosteroids: They precipitate hyperglycaemia (16). Mucormycosis infection is more prevalent in diabetic patients who have been treated for COVID-19 and have taken corticosteroids throughout their treatment (18). Corticosteroids proclivity for impairing migration, ingestion, and phagolysosome fusion in macrophages possibly explain the patient’s reduced immunity (16). Angioinvasive mucormycosis is triggered by a long-term high dose of corticosteroids (19).

Progression to angioinvasion in COVID patients: Vascular endothelial damage, vessel thrombosis, and tissue necrosis are a cascade of events following angioinvasion of mucormycosis (20). Angioinvasiveness results from SARS-CoV-2 facilitated endothelins and modulation of CotH3, GRP78. SARS-CoV-2 facilitated endotheliitis commences due to increased ferritin release in the bloodstream as a response to inflammation; this results in increased free iron. Reactive oxygen species cause oxidative stress and cell membrane lipoperoxidation due to the Fenton reaction of free iron. Free iron and ferritin catalyse endothelial disruption induced by free radicals, spreading endothelial inflammation and promoting endotheliitis (16). Modulation of GRP78, CotH3 (fungal protein) occurs when extracellular grid laminin protein situated on the basement membrane is stimulated by an invasion of an organism in skin or mucosa (21). Thus, the Mucor attaches to endothelial cells with receptor GRP78, found on the host endothelium working with contagious endocytosis (16). The parasitic ligand, which helps in linking the GRP78 during the early intrusion of Mucor, has a place with a spore covering protein family (CotH3) (22). GRP78 is a heat shock protein generated by endothelial cells’ endoplasmic reticulum in response to stress (23). The viral spike-glycoprotein provokes Endoplasmic Reticulum Stress (ERS) and increases GRP78 production during SARS-CoV-2 infection (24). In a prospective case-control research, serum GRP78 was observed to be 5 times more significant in COVID-19 cases than in the test group (16). Additionally, investigations have shown that the SARS-CoV-2 virus utilises GRP78 to internalise into host tissue (24). In the same manner that the virus upregulates GRP78 for its entrance into tissues, it also enhances fungal endocytosis. While GRP78 is a stress-related protein, it is amplified whenever it interacts with ketone bodies on endothelium and high blood glucose (16). The most common form of mucormycosis is a rhino-orbital-cerebral infection, which arises when the fungus infection spreads to orbit and brain parenchyma from paranasal sinuses (25). There are three types of intracranial lesions that emerge as a consequence of rhinocerebral Mucormycosis-a) related to direct venous incursion and necrosis, which includes meningitis, brain abscess, and cranial nerve palsies; b) resulting from vascular injuries, e.g., thrombosis and aneurysm of the cavernous sinus or internal carotid artery, carotid-cavernous fistula, tissue infarction, haemorrhage in subdural space, and brain parenchyma; c) Obstructive hydrocephalus and behavioural changes are afflictions of a space-occupying lesion (26). Orbital Apex syndrome is an unusual thing evidenced by ophthalmoplegia and rapid vision loss involving nerves that directly emerge from the brain: 2nd to 6th, which is deadly (25).

Clinical Features

Mucormycosis can present as an abrupt fulminant or gradual, lethargic intrusive infection. When the cause of immunocompromise is severe, the rate of progression is rapid, whereas when the source of immunocompromise is little or non existent, lethargic intrusive clinical signs appear (4). The disease’s first symptoms are non specific and similar to acute bacterial sinusitis (1). The most prevalent symptoms include rhinorrhea (often explicit), nasal congestion, headache, fever with spikes, face paint and diplopia (1),(11). Thus, clinical features can be divided on basis on stage of disease into: early and late stage features.

In early stage: In the early stages, ischaemic pallor and colour changes appear in the nasal cavity (11). Necrotic eschar or ulcer on nasal septum can be painless. Impairment in vision, diplopia, growth of scar tissue on the bony hard palate, hyperesthesia, and anaesthesia in the oral cavity are seen as the disease progresses with granulation tissue and necrosis of mucosa of the nasal cavity (1). These symptoms are generally determined by the invasion into local anatomical architecture (10). Sinus involvement includes ethmoidal group followed by maxillary, then sphenoidal and frontal (27).

In late stage: The pale or oedematous mucosa (early stage) becomes more vascular, darker, and finally black and necrotic (late-stage) as a result of neurovascular invasion in due course of time. Resulting in ulceration and peeling off the mucosa, leaving crust or a thick eschar (10). Tissue ischaemia due to angiocentric invasion is indicated by white staining of the mucosa, whereas tissue necrosis is shown by black discolouration (28). Clinical staging based on progression and extent are: Stage 1: Rhinomaxillary; Stage 2: Rhino-orbital; Stage 3: Rhino-orbito-cerebral. (Table/Fig 2): Clinical staging based on progression and extent (1).

Diagnostic Methods

The problem is that the initial prodrome may be harmless and non specific (10). The intrusive symptoms that follow might develop quickly and increase in a matter of hours, adding upto the difficulties of getting a timely diagnosis (10). To tackle with this situation, awareness about early signs and symptoms, effective history taking, using highly specific and sensitive laboratory investigations, improvising healthcare facilities can be taken as measure. Investigations consist of blood, histopathological, microbiological, biochemical, and radiological parameters.

Blood investigations: Blood tests are to be done if there is a suspicion of AIFR. The gamut of blood investigations comprises whole blood count, which gives an image of neutropenia or malignancy of blood components, kidney function test, blood glucose ketones, serum iron level, and HIV screening (11). In generalised view, it benefits in knowing about basic blood profile, markers of acute infections, and organ involvement. Disadvantage may include low specificity and sensitivity, not able to know progression of disease, and early involvement of adjacent structures. Blood investigations may not be suitable for diagnosis; therefore, we need further investigations for evaluation for disease.

Histopathological and microbiological: Disease confined to the nasal cavity signals an early stage in the pathophysiology of AIFR; if detected early enough, it is more receptive to total surgical resection by an endoscope, which may improve patient survival (28). Imaging investigations and nasal endoscopy with potential biopsy should be part of an appropriate diagnostic work-up so treatment can begin as soon as possible. The middle turbinates are a cogent site (sensitive+specific) for biopsy (1).

A preliminary diagnosis of mucormycosis based on histological evidence shows broad-based aseptate hyphae (1),(4). Even though tissue specimen may not differentiate between hyphae of species such as aspergillus and mucorlaes but helps in identification of contaminant present (29). Fungal hyphae is highlighted with Toluidine Blue, Haematoxylin and Eosin (H&E), and Gomori Methenamine Stain (GMS) (1),(4). Mucorale hyphae can be seen as non or pauciseptate, branched with bifurcation usually at 90 degree, irregular, and ribbon like (29).

Biochemical: Using fast and in-situ hybridisation for ribosomal RNA aims to identify fungal species that may be a beneficial strategy for identification, which includes Serology, Enzyme-Linked Immunosorbent Assays (ELISA), immunoblots, and immunodiffusion, and sometimes Mucorales specific T cells detection via an enzyme-linked immunospot (ELISpot) assay (1),(29). Above noted, all assays can be used either for detection or identification of Mucorales but most molecular assays target either the Internal Transcribed Spacer (ITS) or the 18S rRNA genes followed by some newer kids in the block, which includes 25 Sribosomal DNA, cytochrome b, PCR coupled to electrospray ionisation mass spectrometry (29),(30),(31).

Radiological: On nasal endoscopy, there will be alterations in the nasal mucosa, granulation tissue, ulcer, and tissue necrosis according to the degree of invasion (1),(3). In all cases of fungal rhinosinusitis, radiography and CT imaging of the nose and paranasal sinuses are performed to determine the openness of the osteomeatal complex, engagement of paranasal sinuses, and attrition of the sinus cavity’s bone borders (32). Plain radiographs show variation from apparently normal to appreciative bony erosion depending on the early and late stages of the disease, respectively (28). Extent of involvement is explicitly exhibited by MRI, which further effectually helps in debridement of devitalised tissue (33). With progressive invasion, a characteristic finding of early-stage rhinosinusitis appears, but it is hard to specify whether the radiograph is of bacterial sinusitis or viral sinusitis (4). CT PNS is favoured over plain radiograph (28). The imaging modality of preference is CT imaging of the sinuses and orbits; however, in the primordial stage of AIFR, 12% of patients show modest alteration, which may or may not be visible due to its fulminant nature (1). The most reliable but non specific imaging feature is hypoattenuating dense mucosa with incomplete or total opacification of solitary one-sided nasal sinus or cavity (1). The occurrence of hyper attenuation patches within opacified sinuses in immunocompromised individuals shows potential danger for elemental fungal aetiology (13). With disease progression, the vascular spread is likely to happen, and also the spread beyond sinuses even though intact bony walls are seen (1). The compartments close to the maxillary sinuses, such as the premaxillary, retro-antral fat, and pterygopalatine fossa, must be painstakingly investigated to study soft tissue infiltration (34). The areas of coagulation necrosis correspond to the absence of contrast enhancement and the presence of a high fungal load (35). Contrast-enhanced MRI is extensively used, and it has been demonstrated to be more efficient than CT at recognising AIFR (11). While CT is perfect for detecting bony alterations, MRI is better for analysing retro-orbital or intracranial extension (1). AIFR has defined different contrast enhancement patterns, such as gadolinium enhanced magnetic resonance imaging (10),(27). Follow-up for scans is essential, particularly in the case of orbital pathologic extension (6).

Treatment

A three-pronged approach to AIFR consists of reversal of risk factors, surgical debridement, and antifungal therapy (10). Controlling the underlying aetiologic immune suppression state is critical to the therapy’s success (1).

Reversal of risk factors: Reversal of diabetic acidosis, hyperglycaemia, iron overload states, electrolyte imbalance, and neutropenia; improvement of circulatory volume and tissue perfusion; cessation of steroid medication; constant removal of ketones from serum and urine seeks to improve immunological status while inhibiting disease progression (1).

Patients with diabetes benefit from aggressive insulin regimens for reversing diabetic Ketoacidosis (1). Iron chelators, such as deferasirox, impede the potential of fungi to reproduce and prevent their spread. As neutrophils play a significant role in antifungal immunity, therapy of granulocyte infusion and granulocyte-macrophage colony-stimulating factor offers great potential in reversing neutropenia (1).

Surgical debridement: Debridement of dead necrotic tissue is to be executed as soon as a normal metabolic state is established (10). Proactive surgical interceding is required for both identifying biopsies and therapeutic debridement, both of which are well recognised as vital parts of management (1). It is necessary to perform extensive surgical debridement with the goal of completely removing necrotic tissue with edges penetrating healthy bleeding tissue (1). This may entail clearing a large amount of nasal mucosa, turbinates and executing extended sinonasal access procedures to clear the sinuses (10). Endoscopic debridement has upgraded from Caldwell-Luc operations and ethmoidectomies, which serves as an advantage and is connected with appealing outcomes because it is minimally invasive, has enhanced visualisation and has reduced operating morbidity (4). For advanced AIFR patients with orbit or intracranial issues, surgical decisions, including maxillectomy and orbital exenteration, which have disfiguring results, can be lifesaving (1),(10). Repeat sessions are frequently required to remove any necrotic tissue that is progressively accumulating (10). Frozen section evaluation during surgery can facilitate the diagnosis and improve prognosis. In the circumstances such as the unavailability of frozen sections along with the risk of acute invasive fungal infection, the clinician should be notified about it straight away without postponing the usual process to be done and report the results to the physician in charge (1).

Antifungal medication: Should indeed be initiated soon after the onset of acute invasive fungal pathology to minimise fatality rates (1). Amphotericin B is efficient on both mucorales and aspergillus species; a dosage of 1-1.5 mg/kg daily intravenous Amphotericin B deoxycholate was given previously (1). Liposomal Amphotericin B (LAB) has become the preliminary medication of choice for management due to its improved tolerance and reduced nephrotoxicity. Unfortunately, the limitation to its long-term utilisation is due to its heavy price. Posaconazole and isavuconazole, two potential novel azoles, have been approved by the FDA as the second line of treatment for mucormycosis (1),(8). They can be taken orally and have a low incidence of side-effects, making them ideal for long outpatient regimens (1). Caspofungin, a new antifungal medication and the first member of the echinocandin family, has demonstrated no effectiveness against mucormycosis in seclusion and exhibits collaborative activity with Amphotericin B (1). Due to its action of liberating oxygen free radicals, oxygen under high pressure directly kills fungi and is thus utilised as a supplementary to management. This adjunct therapy is favourable in diabetic ketoacidosis induced AIFR (1),(10).

Constellation of practical reasons such as omnipresent spores of mucorales, mammoth of susceptible hosts particularly diabetic, disregards regular health check-ups, lead to high prevalence (8). People with oblivious diabetic status, tuberculosis, and chronic kidney disease are at risk. Mortality is linked with delays in medical assistants and severity due to evolved forms. The majority of lacunae in treatment are due to delays in diagnosis, limited medicines, and lesser management alternatives (8).

Prevention: Mucormycosis and its related morbidity and mortality rates necessitate its prevention. Especially in COVID-19, the levels of prevention which can be considered are:

a) Primary level includes vaccination of COVID-19, hygiene and cleanliness, avoiding damp atmosphere, awareness of signs and symptoms planning of outbreaks.
b) Secondary level includes early diagnosis of co-morbidities and its adequate treatment, quarantine and isolation measures. Specific things were observed, which were preventable with judicial use during this era were 21 days of oxygen therapy, steroid usage, prompt treatment of co-morbid conditions.
c) Tertiary level consists of disability limitation and rehabilitation. It is an intervention implemented in already established disease. It helps in better clinical outcome and prevents associated sequalae. When disease progresses into adjacent structures it will worsen the prognosis. As for example, intracranial extension can lead to brain abscess, thrombotic event, intraorbital extension can lead to ophthalmoplegia, and rapid loss of vision as mentioned in above context. Thus, block at such level prevents further disability (36),(37),(38).

Conclusion

Fungal rhinosinusitis (Mucormycosis), caused by mucorales, has a rapid onset and progression. Rhizopus.arrhizhus, Apophysomyces variabilis spp. are the leading causative agents for this surge of cases. It is commonly seen in immunocompromised patients, the earliest sign being loss of sensation (anaesthesia) in an area. Prevention of mucormycosis is at three levels. To prevent fatal outcomes, early diagnosis with frozen biopsy, microscopy using fungal stains, nasal endoscopy; guide us for the type of treatment needed. Reversal of risk factors, aggressive surgical debridement, and antifungal therapy are the three gems of treatment.

References

1.
Singh V. Fungal rhinosinusitis: Unravelling the disease spectrum. J Maxillofac Oral Surg. 2019;18(2):164-79. [crossref] [PubMed]
2.
Fisher MC, Gurr SJ, Cuomo CA, Blehert DS, Jin H, Stukenbrock EH, et al. Threats posed by the fungal kingdom to humans, wildlife, and agriculture. mBio. 2020;11(3):e00449-20. [crossref] [PubMed]
3.
Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, et al. Mucormycosis in immunocompetent patients: A case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2011;15(8):e533-40. [crossref] [PubMed]
4.
Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am. 2000;33(2):349-65. [crossref] [PubMed]
5.
Ananthanarayan and Paniker’s Textbook of Microbiology 10th Edition. General Aspects of Medical Mycology. 2017.
6.
Celis-Aguilar E, Burgos-Páez A, Villanueva-Ramos N, Solórzano-Barrón J, De La Mora-Fernández A, Manjarrez-Velázquez J, et al. An emergent entity: Indolent mucormycosis of the paranasal sinuses. A multicenter study. Int Arch Otorhinolaryngol. 2019;23(1):92-100. [crossref] [PubMed]
7.
Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523. [crossref] [PubMed]
8.
Sharma A, Goel A. Mucormycosis: Risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha). 2022;67(3):363-87. [crossref] [PubMed]
9.
Deek AJ, Boukovalas S, Rathfoot CJ, Gotcher JE. Rhinocerebral mucormycosis as a sequelae of COVID-19 treatment: A case report & literature review. J Oral Maxillofac Surg. 2022;80(2):333-40. [crossref] [PubMed]
10.
Deutsch PG, Whittaker J, Prasad S. Invasive and non invasive fungal rhinosinusitis- a review and update of the evidence. Medicina (Mex). 2019;55(7):319. [crossref] [PubMed]
11.
Craig JR. Updates in management of acute invasive fungal rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2019;27(1):29-36. [crossref] [PubMed]
12.
Slonimsky G, McGinn JD, Goyal N, Crist H, Hennessy M, Gagnon E, et al. A model for classification of invasive fungal rhinosinusitis by computed tomography. Sci Rep. 2020;10(1):12591. [crossref] [PubMed]
13.
Raz E, Win W, Hagiwara M, Lui YW, Cohen B, Fatterpekar GM. Fungal sinusitis. neuroimaging. Clin N Am. 2015;25(4):569-76. [crossref] [PubMed]
14.
Kulkarni AP, Siddiqui SS. Systemic Fungal Infections. API Textbook of Medicine 11th Edition. Volume 1. 2019.
15.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54 Suppl 1:S16-22. [crossref] [PubMed]
16.
Jose A, Singh S, Roychoudhury A, Kholakiya Y, Arya S, Roychoudhury S. Current understanding in the pathophysiology of SARS-CoV-2-associated rhino-orbito-cerebral mucormycosis: A comprehensive review. J Maxillofac Oral Surg. 2021;20(3):373-80. [crossref] [PubMed]
17.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54 Suppl 1:S23-34. [crossref] [PubMed]
18.
Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):418-25. [crossref] [PubMed]
19.
Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216-24. [crossref] [PubMed]
20.
Shumilov E, Bacher U, Perske C, Mohr A, Eiffert H, Hasenkamp J, et al. In situ validation of the endothelial cell receptor GRP78 in a case of rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2018;62(5):e00172-18.[crossref] [PubMed]
21.
Chandley P, Subba P, Rohatgi S. COVID-19-associated mucormycosis: A matter of concern amid the SARS-CoV-2 pandemic. Vaccines. 2022;10(8):1266. [crossref] [PubMed]
22.
Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest. 2014;124(1):237-50. [crossref] [PubMed]
23.
Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: A cell’s response to stress. Life Sci. 2019;226:156-63. [crossref] [PubMed]
24.
Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect. 2020;80(5):554-62. [crossref] [PubMed]
25.
Saldanha M, Reddy R, Vincent MJ. Title of the article: Paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 2):3407-10. [crossref] [PubMed]
26.
Bhandari J, Thada PK, Nagalli S. Rhinocerebral Mucormycosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Nov 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559288/.
27.
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442-47. [crossref] [PubMed]
28.
Mundra RK, Gupta Y. Mucormycosis of nose and paranasal sinuses with orbital complication in young diabetic. Indian J Otolaryngol Head Neck Surg. 2008;60(4):360-64. [crossref] [PubMed]
29.
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93-101. [crossref] [PubMed]
30.
Mudgal S, Rao S, Pai M. Mucormycosis: A comparative update between conventional and molecular diagnosis strategies. Curr Med Mycol. 2022;8:44-53. [crossref] [PubMed]
31.
Liu J, Yu Y, Cai Z, Bartlam M, Wang Y. Comparison of ITS and 18S rDNA for estimating fungal diversity using PCR-DGGE. World J Microbiol Biotechnol. 2015;31(9):1387-95. [crossref] [PubMed]
32.
Suresh S, Arumugam D, Zacharias G, Palaninathan S, Vishwanathan R, Venkatraman V. Prevalence and clinical profile of fungal rhinosinusitis. Allergy Rhinol. 2016;7(2):e115-20. [crossref] [PubMed]
33.
Sundaram N, Bhende T, Yashwant R, Jadhav S, Jain A. Mucormycosis in COVID- 19 patients. Indian J Ophthalmol. 2021;69(12):3728-33. [crossref] [PubMed]
34.
Deshmukh YA, Vaid S, Chandorkar A, Atre A, Patil S. Imaging spectrum of rhino- orbital-cerebral mucormycosis secondary to COVID-19 infection: A reporting checklist. Pol J Radiol. 2022;87:e333-47. [crossref] [PubMed]
35.
Choi YR, Kim JH, Min HS, Won JK, Kim HJ, Yoo RE, et al. Acute invasive fungal rhinosinusitis: MR imaging features and their impact on prognosis. Neuroradiology. 2018;60(7):715-23. [crossref] [PubMed]
36.
Ish P, Ish S. Prevention of mucormycosis in COVID-19-the need of the hour. Indian J Ophthalmol. 2021;69(7):1969. [crossref] [PubMed]
37.
Mucormycosis infographics [Internet]. [cited 2022 Nov 2]. Available from: https:// www.who.int/southeastasia/outbreaks-and-emergencies/covid-19/What-can-we-do-to-keep-safe/mucormycosis.
38.
Kisling LA, Das JM. Prevention strategies. InStatPearls [Internet] 2021 May 9. StatPearls Publishing.

DOI and Others

DOI: 10.7860/JCDR/2023/59617.17471

Date of Submission: Aug 11, 2022
Date of Peer Review: Oct 15, 2022
Date of Acceptance: Nov 10, 2022
Date of Publishing: Feb 01, 2023

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. No

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Aug 22, 2022
• Manual Googling: Oct 26, 2022
• iThenticate Software: Nov 28, 2022 (6%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com